HC Wainwright Expects Lower Earnings for Zevra Therapeutics

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for Zevra Therapeutics in a report released on Tuesday, June 9th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of $0.46 for the year, down from their prior forecast of $1.06. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is $0.56 per share. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2028 earnings at $0.82 EPS, FY2029 earnings at $1.58 EPS and FY2030 earnings at $2.49 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%.The firm had revenue of $36.22 million during the quarter, compared to analyst estimates of $31.96 million.

A number of other equities analysts have also commented on the company. BTIG Research reaffirmed a “buy” rating and issued a $27.00 price target (up from $23.00) on shares of Zevra Therapeutics in a report on Tuesday. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a report on Tuesday. Weiss Ratings lowered Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Friday, May 22nd. Wall Street Zen lowered Zevra Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Citizens Jmp raised their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “market outperform” rating in a report on Tuesday. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $29.29.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $13.50 on Thursday. Zevra Therapeutics has a one year low of $7.16 and a one year high of $14.27. The business has a fifty day moving average price of $10.55 and a 200-day moving average price of $9.45. The firm has a market capitalization of $798.12 million, a P/E ratio of 6.78 and a beta of 0.91.

Institutional Investors Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. ProShare Advisors LLC raised its position in shares of Zevra Therapeutics by 12.3% in the fourth quarter. ProShare Advisors LLC now owns 12,669 shares of the company’s stock worth $114,000 after buying an additional 1,390 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Zevra Therapeutics by 9.4% in the second quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company’s stock worth $179,000 after buying an additional 1,750 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Zevra Therapeutics by 6.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock worth $238,000 after buying an additional 1,812 shares in the last quarter. Deutsche Bank AG raised its position in shares of Zevra Therapeutics by 4.4% in the fourth quarter. Deutsche Bank AG now owns 45,939 shares of the company’s stock worth $412,000 after buying an additional 1,936 shares in the last quarter. Finally, MetLife Investment Management LLC raised its position in shares of Zevra Therapeutics by 10.5% in the fourth quarter. MetLife Investment Management LLC now owns 27,867 shares of the company’s stock worth $250,000 after buying an additional 2,653 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.